Outcomes, Outcomes, Outcomes: Why Pharma Companies Need to Reorganize—Quickly—to Show Value

Posted by Ian Wilcox

Pharma pricing is in the headlines once again, this time thanks to the machinations of Martin Shrekli, the now notorious CEO of Turing Pharmaceuticals.

They say any publicity is good publicity. I’m not so sure. Rarely has pricing sparked as much controversy as it has these past few weeks. A conversation normally confined to the staid precincts of the business pages erupted onto social media, as Shrekli’s move to kick up the price of Daraprim by 5000% aroused the collective scorn of the media and internet.

Shrekli’s actions even led Hillary Clinton to pledge to fight high pharma prices, which sent the price of the NASDAQ biotech index Read more

Recent blog posts  

Latest video blog

Subscribe to our mailing list now!

To access our latest thinking and get regular updates fill in your email address below

More from Hay Group

Our authors

Inspired thinkers, experienced professionals, view here.